Valeo Pharma Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kyle Steiger
- Full Time Employees
- 70
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 16667 Hymus Boulevard Kirkland QC Canada H9H 4R9
- IPO Date
- Sep 23, 2020
- Website
- valeopharma.com
- Similar Companies
- Business
- Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF), a Canadian specialty pharmaceutical company, licenses, acquires, and commercializes innovative prescription drugs and hospital products primarily for the Canadian market, with a portfolio focused on respiratory/allergy, ophthalmology, neurology, oncology, and specialty therapeutic areas. The company offers a diverse range of branded products, including Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple combination inhaler for asthma; Atectura Breezhaler, a LABA/ICS dual combination inhaler for asthma; Onstryv (safinamide), for the treatment of idiopathic Parkinson's disease; Redesca, an anticoagulant to treat and prevent deep vein thrombosis and pulmonary embolism; M-Eslon, extended-release morphine sulphate for pain management; Yondelis (trabecteddin), for soft tissue sarcoma; Hesperco, a flavonoid immune support formulation; and others such as Ethacrynate Sodium and Amikacin antibiotics, alongside ophthalmology solutions like those previously associated with XIIDRA. Founded in 2003 and headquartered in Kirkland, Quebec, Valeo Pharma operates with full infrastructure for product registration, commercialization, and distribution across Canada, serving healthcare professionals and patients in unmet medical needs segments. In a major strategic development, Valeo Pharma closed a share purchase agreement with Xediton Pharmaceuticals Inc. in February 2025, enabling portfolio revitalization, expanded innovative offerings, resource synergies, and sustained growth under Xediton's leadership while preserving jobs and stakeholder commitments.
Valeo Pharma adds chief development officer to drive growth initiatives
Valeo Pharma sees record 2Q revenue boosted by respiratory products and core brand growth
Valeo Pharma restructures field operations to save over $5m annually
Valeo Pharma taps life sciences leader for board position
Valeo Pharma sees 1Q revenue increase on strong performance from respiratory division
Valeo Pharma unveils boardroom reshuffle
Valeo Pharma amends Novartis eye treatment distribution agreement
Valeo Pharma achieves record revenues for fiscal 2023
Valeo Pharma announces cost-reduction initiatives as it welcomes new CFO
Valeo Pharma welcomes Richard Lajoie to board of directors
Valeo Pharma CEO credits Enerzair for strong position on Canada's top-growing companies list
Valeo Pharma secures spot on Canada's top-growing companies list
Valeo Pharma secures $5M credit facility agreement with Accord Financial
Valeo Pharma reports record quarterly revenue or strong demand for Enerzair and Atectura therapies
Valeo Pharma raises funds totalling $4.5M
Valeo Pharma bolsters board with two new directors
Valeo Pharma reports record quarterly revenues
Valeo Pharma expects 2Q revenues to set quarterly record
Valeo Pharma reports record 1Q revenue and gross profit buoyed by new products and higher market share
Valeo Pharma obtains public reimbursement for Onstryv in Quebec expanding access to the drug for Parkinson's patients